Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute

SANTA MONICA, Calif.--(BUSINESS WIRE) July 20, 2017 -- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlighted the recent online publication of results in Molecular Therapy from a National Cancer Institute (NCI) study of... (Source: Drugs.com - Clinical Trials)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2gWeEtP
via IFTTT